Compare · EDSA vs PDSB
EDSA vs PDSB
Side-by-side comparison of Edesa Biotech Inc. (EDSA) and PDS Biotechnology Corporation (PDSB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EDSA and PDSB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PDSB is the larger of the two at $55.8M, about 1.2x EDSA ($47.7M).
- Over the past year, EDSA is up 189.9% and PDSB is down 41.5% - EDSA leads by 231.4 points.
- EDSA has been more active in the news (15 items in the past 4 weeks vs 1 for PDSB).
- PDSB has more recent analyst coverage (3 ratings vs 1 for EDSA).
- Company
- Edesa Biotech Inc.
- PDS Biotechnology Corporation
- Price
- $5.30-4.24%
- $1.00-2.44%
- Market cap
- $47.7M
- $55.8M
- 1M return
- -69.25%
- -13.42%
- 1Y return
- +189.89%
- -41.52%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 15
- 1
- Recent ratings
- 1
- 3
Edesa Biotech Inc.
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
PDS Biotechnology Corporation
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
Latest EDSA
- Edesa Biotech Inc. filed SEC Form 8-K: Other Events
- Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
- Chief Executive Officer Nijhawan Pardeep was granted 1,671 shares, increasing direct ownership by 0.23% to 731,134 units (SEC Form 4)
- Director Marshall Patrick was granted 19,000 shares, increasing direct ownership by 36% to 71,666 units (SEC Form 4)
- Director Macdonald Sean Arthur was granted 19,000 shares, increasing direct ownership by 86% to 41,054 units (SEC Form 4)
- Director Chypyha Joan was granted 19,000 shares, increasing direct ownership by 172% to 30,029 units (SEC Form 4)
- Chief Financial Officer Weiler Peter J. was granted 64,609 shares, increasing direct ownership by 99% to 129,609 units (SEC Form 4)
- President Brooks Michael J was granted 64,609 shares, increasing direct ownership by 28% to 291,479 units (SEC Form 4)
- Director Sistilli Carlo was granted 19,000 shares, increasing direct ownership by 62% to 49,417 units (SEC Form 4)
- Director Olson Charles V was granted 19,000 shares, increasing direct ownership by 173% to 30,000 units (SEC Form 4)
Latest PDSB
- PDS Biotechnology Corporation filed SEC Form 8-K: Other Events
- SEC Form 10-Q filed by PDS Biotechnology Corporation
- PDS Biotechnology Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
- PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results
- PDS Biotechnology Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities
- SEC Form EFFECT filed by PDS Biotechnology Corporation
- Amendment: SEC Form 10-K/A filed by PDS Biotechnology Corporation
- Amendment: SEC Form S-3/A filed by PDS Biotechnology Corporation
- PDS Biotechnology Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits